EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Severe COVID-19 Outcomes in Five Latin American Countries in the Postvaccination Era

Guilherme Silva Julian iD, Júlia Spinardi, Melissa Diaz-Puentes, Diana Buitrago iD, Ida Caterina García, Moe H Kyaw iD

Viruses · 2024

DOI: 10.3390/v16071025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Guilherme Silva Julian und 5 weiteren Autor:innen. Beteiligte Einrichtung: Evidence Generation Medical Affairs, Pfizer Inc., São Paulo 04717-904, Brazil. Hauptthemen laut MEDLINE: COVID-19, Hospitalization, COVID-19 Vaccines, SARS-CoV-2. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We conducted a multicountry retrospective study using data from COVID-19 national surveillance databases to analyze clinical profiles, hospitalization rates, intensive care unit (ICU) admissions, utilization of ventilatory support, and mortality rates in five Latin American countries in the context of COVID-19 vaccination implementation. We analyzed the sociodemographic characteristics, comorbidities, clinical outcomes, and vaccination status of laboratory-confirmed COVID-19 cases from January 2021 to December 2022. We calculated the yearly and quarterly hospitalization rates per 1000 confirmed COVID-19 cases and ICU admissions, use of mechanical ventilators, and mortality rates per 1000 hospitalized cases, with their corresponding 95% confidence interval (CI) of 38,852,831 confirmed COVID-19 cases. Rates of hospitalization, ICU admission, ventilatory support, and death were higher among males than among females (38.2 vs. 32.4, 148.4 vs. 117.7, 282.9 vs. 236.2, and 346.9 vs. 320.1 per 1000, respectively); higher in 2021 than in 2022 (50.7 vs. 19.9, 207.8 vs. 58.2, 441.5 vs. 114.9, and 352.5 vs. 285.2 per 1000, respectively); and in the >50 age group (range: 5.7–18.6, 20.1–71.5, 12.2–67.9, and 353.1–577.4, per 1000) than the

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HospitalizationCOVID-19 VaccinesSARS-CoV-2HumansMaleFemaleLatin AmericaMiddle AgedRetrospective StudiesAdultAgedComorbidityIntensive Care UnitsYoung AdultAdolescentVaccinationRespiration, Artificial

Stichwörter der Autor:innen

COVID-19Latin Americacoronavirusfatal outcomeshospitalization raterisk factors

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Evidence Generation Medical Affairs, Pfizer Inc., São Paulo 04717-904, Brazil.
  • Vaccines Medical Affairs, Pfizer Inc., São Paulo 04717-904, Brazil.
  • Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo 01224-001, Brazil.
  • Real World Insights (RWI), IQVIA, Bogotá 110110, Colombia.
  • Real World Insights (RWI), IQVIA, Ciudad de México C.P. 03810, Mexico.
  • Vaccines Clinical Epidemiologist Emerging Markets, Pfizer Inc., Collegeville, PA 19426-3982, USA.

ORCID-Profile: Guilherme Silva Julian, Diana Buitrago, Moe H Kyaw

Förderung

  • Pfizer

Zitieren

APA

Silva Julian, G., Spinardi, J., Diaz-Puentes, M., Buitrago, D., García, I. C., & Kyaw, M. H. (2024). Severe COVID-19 Outcomes in Five Latin American Countries in the Postvaccination Era. Viruses. https://doi.org/10.3390/v16071025

Vancouver

Silva Julian G, Spinardi J, Diaz-Puentes M, Buitrago D, García IC, Kyaw MH. Severe COVID-19 Outcomes in Five Latin American Countries in the Postvaccination Era. Viruses. 2024. doi:10.3390/v16071025

BibTeX
@article{SilvaJulian2024,
  author = {Silva Julian, Guilherme and Spinardi, Júlia and Diaz-Puentes, Melissa and Buitrago, Diana and García, Ida Caterina and Kyaw, Moe H},
  title = {Severe COVID-19 Outcomes in Five Latin American Countries in the Postvaccination Era},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16071025}
}
Kostenlos starten →